Free Trial
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$192.17
+1.1%		$125.46
$22.28
▼
$208.90
$76.72B1.0911.88 million shs2.28 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$728.09
-1.0%		$788.30
$541.00
▼
$859.34
$74.96B0.16826,556 shs68,368 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$202.30
-2.1%		$202.80
$45.80
▼
$224.31
$43.36B1.42.87 million shs254,829 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$499.56
-1.0%		$519.58
$400.73
▼
$560.25
$126.79B0.281.37 million shs82,496 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-4.46%+30.55%+132.29%+566.94%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%-6.71%-11.18%+13.14%+22.53%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.00%+0.81%-1.61%+8.76%+342.39%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.00%-4.08%-7.58%-4.69%+25.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$192.17
+1.1%		$125.46
$22.28
▼
$208.90
$76.72B1.0911.88 million shs2.28 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$728.09
-1.0%		$788.30
$541.00
▼
$859.34
$74.96B0.16826,556 shs68,368 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$202.30
-2.1%		$202.80
$45.80
▼
$224.31
$43.36B1.42.87 million shs254,829 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$499.56
-1.0%		$519.58
$400.73
▼
$560.25
$126.79B0.281.37 million shs82,496 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-4.46%+30.55%+132.29%+566.94%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%-6.71%-11.18%+13.14%+22.53%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.00%+0.81%-1.61%+8.76%+342.39%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.00%-4.08%-7.58%-4.69%+25.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$77.83-59.50% Downside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.69
Moderate Buy$809.5011.18% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.96
Moderate Buy$234.3315.84% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.96
Moderate Buy$575.1315.13% Upside

Current Analyst Ratings Breakdown

Latest RVMD, VRTX, REGN, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
10/1/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$870.00 ➝ $930.00
10/1/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$850.00
9/30/2026
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$60.00 ➝ $80.00
9/29/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSector Perform$737.00
9/28/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$585.00 ➝ $615.00
9/28/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
9/28/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$318.00
9/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/24/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$267.00
9/24/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$267.00
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B39.47N/AN/A$22.14 per share8.68
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.23$41.58 per share17.51$295.66 per share2.46
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,744.42N/AN/A$8.44 per share23.97
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$12.00B10.56$17.39 per share28.72$73.57 per share6.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4618.0013.981.4127.86%13.47%10.34%10/30/2026 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%11/4/2026 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.95B$17.1829.0827.222.2135.00%23.09%16.72%11/2/2026 (Estimated)

Latest RVMD, VRTX, REGN, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/2/2026Q3 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.76N/AN/AN/A$3.41 billionN/A
10/30/2026Q3 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$15.99N/AN/AN/A$4.54 billionN/A
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
8/3/2026Q2 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.74$4.73-$0.01$4.31$3.23 billion$3.33 billion
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.52%N/A9.29%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest RVMD, VRTX, REGN, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.46%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/A
3.19
2.74

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
883214.34 million198.05 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,400253.80 million253.30 millionOptionable

Recent News About These Companies

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
 |  zacks.comhttps://www.zacks.com/stock/news/2999987/vertex-pharmaceuticals-incorporated-vrtx-is-attracting-investor-attention-here-is-what-you-should-know?cid=cs-stocknewsapi-ft-fundamental_analysis|most_searched_stocks_v1-2999987
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-incorporated-vrtx-attracting-120007627.html
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
October 4 at 10:14 AM  |  fool.comhttps://www.fool.com/coverage/better-buy/2026/10/04/amgen-vs-vertex-pharmaceuticals-which-biotech-stock-is-a-better-buy-in-2026/
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Crosses Above 200 Day Moving Average - Here's Why
October 3 at 2:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081583
Vertex Pharmaceuticals (NASDAQ:VRTX) Share Price Crosses Above Two Hundred Day Moving Average - What's Next?
October 3 at 1:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vertex-pharmaceuticals-nasdaq-vrtx-share-price-crosses-above-two-hundred-day-moving-average-whats-next-2026-10-03/
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
October 2 at 11:06 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vertex-vrtx-regeneron-regn-two-024009734.html
CRISPR Therapeutics to Present Phase 1 Data on Zugo-cel in Refractory Systemic Sclerosis at ACR Convergence 2026
October 2 at 10:30 AM  |  quiverquant.comQ
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-vrtx-stock-falls-210006610.html
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-2-other-top-220722974.html
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
October 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2999228/vertex-pharmaceuticals-vrtx-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v2-2999228
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
October 1, 2026  |  fool.comhttps://www.fool.com/coverage/better-buy/2026/10/01/axsome-therapeutics-vs-vertex-pharmaceuticals-which-biotech-stock-is-a-better-buy-in-2026/
The Top HealthTech Questions Landing on Our Desks
September 30, 2026  |  etftrends.comE
Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade
September 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950636-vertex-stock-still-too-much-emphasis-on-cf-supremacy-i-foresee-rating-downgrade?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
September 29, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/29/2-wall-street-analysts-think-vertex-may-soar/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=f5a22054-2c3a-46c9-8d92-39aea9607e62
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
September 29, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/29/2-wall-street-analysts-think-vertex-may-soar/
2 Healthcare Stocks to Target This Week and 1 We Avoid
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/2-healthcare-stocks-target-week-103836911.html
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/could-vertex-pharmaceuticals-vrtx-kidney-003708108.html
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
September 28, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/could-vertex-pharmaceuticals-vrtxs-kidney-breakthrough-unlock-a-new-opportunity-for-maze-therapeutics-maze-1846012/
2 Healthcare Stocks That Just Delivered Great News for Investors
September 26, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/26/2-healthcare-stocks-that-just-delivered-great-news-for-investors/
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Envestnet Asset Management Inc.
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-sold-by-envestnet-asset-management-inc-2026-09-25/
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-vrtx-increases-despite-205006588.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Moderna stock logo

Moderna NASDAQ:MRNA

$192.17 +2.16 (+1.14%)
As of 10:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$728.09 -7.11 (-0.97%)
As of 10:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$202.30 -4.34 (-2.10%)
As of 10:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$499.56 -5.17 (-1.02%)
As of 10:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas